AZN : Summary for Astrazeneca PLC Common Stock - Yahoo Finance

U.S. Markets closed

AstraZeneca PLC (AZN)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
27.07-0.84 (-3.01%)
At close: 4:02PM EST

26.78 -0.29 (-1.08%)
After hours: 5:19PM EST

People also watch
GSKNVSSNYLLYBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close27.91
Open27.39
Bid0.00 x
Ask0.00 x
Day's Range26.86 - 27.42
52 Week Range25.55 - 35.04
Volume10,124,635
Avg. Volume7,633,472
Market Cap68.23B
Beta0.56
PE Ratio (TTM)30.94
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.90 (3.16%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters57 minutes ago

    Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

    Bristol-Myers Squibb Co (BMY.N) shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's (MRK.N) leading position in the burgeoning immuno-oncolgy field. Lung cancer is by far the biggest oncology market and a handful of companies have been battling to become dominant in initial, or first-line, treatment, and to provide much-needed combination therapies. Merck shares rose 3.6 percent to $62.53, while Bristol fell to $49.23.

  • Accesswire10 hours ago

    Blog Coverage AbbVie Received FDA Approval for Treatment for Marginal Zone Lymphoma

    Upcoming AWS Coverage on AstraZeneca LONDON, UK / ACCESSWIRE / January 20, 2017 / Active Wall St. blog coverage looks at the headline from AbbVie Inc. (NYSE: ABBV ) as the Company announced on January ...

  • Financial Timesyesterday

    [$$] GSK appoints AstraZeneca executive as global head of pharma

    GlaxoSmithKline has poached its new global head of pharmaceuticals from rival AstraZeneca, marking a change of guard at Britain's biggest drugmaker as it prepares for the arrival of its new chief executive. ...